UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 744

Sortiert nach

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

The journal of clinical endocrinology and metabolism, 2013-06, Vol.98 (6), p.2392-2400

2013

Volltextzugriff (PDF)

Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines

Journal of dental research, 2011-05, Vol.90 (5), p.638-645

2011

Volltextzugriff (PDF)

Absence of BRAF mutations in UV-protected mucosal melanomas

Journal of medical genetics, 2004-04, Vol.41 (4), p.270-272

2004

Volltextzugriff (PDF)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

Annals of oncology, 2019-02, Vol.30 (2), p.325-331

2019

Volltextzugriff (PDF)

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK

Oncogene, 2011-01, Vol.30 (1), p.87-96

2011

Volltextzugriff (PDF)

Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Annals of oncology, 2018-10, Vol.29, p.viii373-viii373

2018

Volltextzugriff (PDF)

Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program

JNCI : Journal of the National Cancer Institute, 2002-09, Vol.94 (18), p.1365-1372

2002

Volltextzugriff (PDF)

The RET/PTC3 oncogene activates classical NF-[kappa]B by stabilizing NIK

Oncogene, 2011-01, Vol.30 (1), p.87

2011

Volltextzugriff (PDF)

Germline CHEK21100delC mutations in breast cancer patients with multiple primary cancers

Journal of medical genetics, 2004-11, Vol.41 (11), p.e120-e120

2004

Volltextzugriff (PDF)

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

The New England journal of medicine, 2023-11, Vol.389 (20), p.1851-1861

2023

Volltextzugriff (PDF)

1046OPreliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology

Journal of clinical oncology, 2015-03, Vol.33 (7), p.786-809

2015

Volltextzugriff (PDF)

New molecular targets in melanoma

Current opinion in oncology, 2004-03, Vol.16 (2), p.150-154

Flaherty, Keith T

2004

Volltextzugriff (PDF)

Sorafenib Delays Progression of Treatment-Resistant Differentiated Thyroid Cancer

MD conference express, 2013-07, Vol.13 (6), p.13-13

2013

Volltextzugriff (PDF)

BRAF and RAS mutations in human lung cancer and melanoma

Cancer research (Chicago, Ill.), 2002-12, Vol.62 (23), p.6997-7000

2002

Volltextzugriff (PDF)

Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS263-TPS263

2010

Volltextzugriff (PDF)

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation

Cancer research (Chicago, Ill.), 2003-02, Vol.63 (4), p.756-759

2003

Volltextzugriff (PDF)

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

Journal of the American Academy of Dermatology, 2012-12, Vol.67 (6), p.1265-1272

2012

Volltextzugriff (PDF)

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer

Baillière's best practice & research. Clinical endocrinology & metabolism, 2017-06, Vol.31 (3), p.295-305

2017

Volltextzugriff (PDF)

Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype

Chest, 2013-05, Vol.143 (5), p.1302-1311

2013

Volltextzugriff (PDF)

Phase II trial of sorafenib in patients with advanced thyroid cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5562-5562

2011

Volltextzugriff (PDF)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

Annals of oncology, 2019-02, Vol.30 (2), p.325

2019

Volltextzugriff (PDF)

Characterization of two novel BRCA1 germ-line mutations involving splice donor sites

Genetic testing, 2004-06, Vol.8 (2), p.133-138

2004

Volltextzugriff (PDF)

1 – 25 von 744

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(632)
Mit Volltextzugriff
(690)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines

Absence of BRAF mutations in UV-protected mucosal melanomas

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK

Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program

The RET/PTC3 oncogene activates classical NF-[kappa]B by stabilizing NIK

Germline CHEK21100delC mutations in breast cancer patients with multiple primary cancers

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

1046OPreliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology

New molecular targets in melanoma

Sorafenib Delays Progression of Treatment-Resistant Differentiated Thyroid Cancer

BRAF and RAS mutations in human lung cancer and melanoma

Phase II trial of everolimus with sorafenib for patients with differentiated thyroid cancer (DTC) who progress on sorafenib alone

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer

Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype

Phase II trial of sorafenib in patients with advanced thyroid cancer

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

Characterization of two novel BRCA1 germ-line mutations involving splice donor sites

Suchergebnisse filtern